MEI Pharma, Inc. (MEIP)

[Pennybuster]

Nice SA Article Out This Morning. $MEIP Will Get Attention Here.








MEI Pharma: ASH Abstract Data Supports Advancement Of Pracinostat In MDS And AML
Nov. 11, 2015 7:54 AM ET | About: MEI Pharma, Inc. (MEIP)
Disclosure: I am/we are long MEIP. (More...)
Summary

Hazard ratios strongly favor Pracinostat compared to placebo in MDS trial for survival, progression free survival and event free survival in patients tolerating combo.

Abstract reveals goal of 12 month median overall survival already achieved in elderly AML trial.

Management communicated that as of today the median overall survival is still not reached in AML trial, adding at least another 3 months to abstract data.

Sitting at ~$60M market cap, near cash on hand, I expect shares to run-up in anticipation of ASH and much higher following results and analyst feedback.

I wrote an article last week detailing why investors should buy MEI Pharma (NASDAQ:MEIP) before the American Society of Hematology (NYSE:ASH) meeting on Decemeber 7th where updated data will be presented for their lead drug Pracinostat in Acute Myeloid Leukemia and Myelodysplastic Syndrome. The two abstracts for the presentation were released last Thursday and the data is more impressive than I anticipated for both MDS and AML. Investors sold on the news, likely taking profits from the ~30% run-up the last two weeks. I've been getting a lot of emails regarding my take on the abstracts so I thought it would be easier to release a brief summary explaining the updated data which clearly illustrates that the target overall survival metric needed to move Pracinostat into Phase 3 for elderly AML has already been achieved and why the MDS indication could be back on the table. I reiterate my position and look for a nice run-up leading into ASH.






SA Link.



http://seekingalpha.com/article/3675316-mei-pharma-ash-abstract-data-supports-advancement-of-pracinostat-in-mds-and-aml